Nisa Investment Advisors LLC Boosts Stake in Insmed Incorporated (NASDAQ:INSM)

Nisa Investment Advisors LLC grew its stake in Insmed Incorporated (NASDAQ:INSM) by 5.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,533 shares of the biopharmaceutical company’s stock after acquiring an additional 183 shares during the period. Nisa Investment Advisors LLC’s holdings in Insmed were worth $244,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. V Square Quantitative Management LLC purchased a new position in Insmed in the third quarter valued at about $30,000. GAMMA Investing LLC grew its stake in shares of Insmed by 71.3% during the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 224 shares during the last quarter. Exchange Traded Concepts LLC lifted its stake in shares of Insmed by 522.5% during the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 627 shares during the period. Blue Trust Inc. raised its stake in shares of Insmed by 2,348.8% in the third quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company’s stock worth $131,000 after purchasing an additional 1,879 shares during the last quarter. Finally, JCIC Asset Management Inc. acquired a new stake in shares of Insmed in the third quarter worth $133,000.

Wall Street Analysts Forecast Growth

INSM has been the topic of several recent research reports. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price target on shares of Insmed in a report on Friday, November 1st. Truist Financial reaffirmed a “buy” rating and set a $105.00 target price (up from $100.00) on shares of Insmed in a report on Friday, November 1st. Bank of America lifted their price objective on shares of Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a report on Wednesday, October 9th. Finally, JPMorgan Chase & Co. upped their target price on Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a research note on Friday, November 22nd. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, Insmed has an average rating of “Moderate Buy” and an average target price of $83.67.

Insmed Trading Down 0.6 %

INSM opened at $78.00 on Thursday. Insmed Incorporated has a one year low of $21.92 and a one year high of $80.53. The business’s 50 day moving average price is $72.28 and its 200 day moving average price is $72.97. The stock has a market capitalization of $13.95 billion, a PE ratio of -14.05 and a beta of 1.12. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The firm had revenue of $93.40 million for the quarter, compared to analyst estimates of $93.36 million. During the same quarter last year, the business earned ($1.10) earnings per share. The business’s revenue for the quarter was up 18.1% on a year-over-year basis. As a group, equities research analysts expect that Insmed Incorporated will post -5.44 EPS for the current year.

Insider Buying and Selling at Insmed

In other news, CFO Sara Bonstein sold 3,470 shares of the stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $65.70, for a total value of $227,979.00. Following the transaction, the chief financial officer now owns 114,736 shares in the company, valued at approximately $7,538,155.20. This represents a 2.94 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO William Lewis sold 31,805 shares of Insmed stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $70.18, for a total transaction of $2,232,074.90. Following the sale, the chief executive officer now owns 379,534 shares in the company, valued at $26,635,696.12. This represents a 7.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 104,740 shares of company stock valued at $7,161,294 in the last three months. 4.60% of the stock is owned by corporate insiders.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.